Showing 1 - 10 of 109
Persistent link: https://www.econbiz.de/10002004677
The aim of this paper is to empirically analyse the responses by general practitioners to promotional activities for ethical drugs by pharmaceutical companies. Promotion can be beneficial as a means of providing information, but it can also be harmful in the sense that it lowers price...
Persistent link: https://www.econbiz.de/10014058923
Persistent link: https://www.econbiz.de/10003274073
The aim of this paper is to empirically analyse the responses by general practitioners to promotional activities for pharmaceuticals by pharmaceutical companies. Promotion can be beneficial as a means of providing information, but it can also be harmful in the sense that it lowers price...
Persistent link: https://www.econbiz.de/10014072054
Persistent link: https://www.econbiz.de/10001592896
Persistent link: https://www.econbiz.de/10001992667
Persistent link: https://www.econbiz.de/10002473024
Since 2003, a new set of scenario-analyses have been published by the CPB in Four Futures of Europe (de Mooij and Tang, 2003), four scenarios are sketched for the development of the European economy until 2040. The scenarios are defined in terms of two groups of 'key uncertainties'. The first...
Persistent link: https://www.econbiz.de/10014049360
This study presents four long term scenarios for government and health care services in the Netherlands. In 2001, the expenditure on government and health care services (including pharmaceuticals) was about 24% of Dutch GDP. According to all scenarios this will increase to between 29% and 33% of...
Persistent link: https://www.econbiz.de/10013066486
Persistent link: https://www.econbiz.de/10003337323